Effects of BRS and LRS on Postoperative Acute Kidney Injury
NCT ID: NCT04835038
Last Updated: 2023-04-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
3400 participants
INTERVENTIONAL
2021-06-01
2023-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
2. Objective: To evaluate the effect of BRS and LRS infusion on acute renal injury in patients undergoing major abdominal surgery
3. Primary outcome: Incidence of AKI at 28 days postoperative (defined as acute kidney injury, according to Kidgo 2012 definition and classification).
4. Study Design: Randomized, controlled, open-label clinical study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Application of Sodium Bicarbonate Ringer's Solution in Laparoscopic Hepatectomy
NCT05830136
Sodium Bicarbonate Ringer's Solution for Preventing and Treating Hyperlactacidemia During Hepatectomy
NCT04547296
Sodium Bicarbonate Ringer's Solution Versus Normal Saline for Early Fluid Resuscitation in Patients With Sepsis
NCT04621981
Safety and Efficacy of Perioperative Volume Replacement with Volulyte 6% in Moderate-to-high Cardiovascular Risk Patients Having Major Abdominal Surgery
NCT06663254
Risk Potential for Organ Dysfunction Associated With Sodium Bicarbonate Therapy (SBT) in Critically Ill Patients
NCT04953013
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
2. Study data collection period: Subjects signed the consent form until 28 days after discharge or died in hospital or withdrew from the study.
3. Number of research centers/sample size: 3400 patients were planned to be included.
4. Study process: Among patients undergoing elective surgery, the researchers will include patients who meet the inclusion criteria for elective major abdominal surgery and agree to participate in the study. The data to be collected in this study will be recorded by the researcher in the eCRF, including:
(1) Data to be collected during the screening period and preoperatively: patients' basic characteristics and demographic data (2) Data to be recorded during and/or after surgery: primary study indicators, secondary indicators, and other indicators.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sodium Bicarbonate Ringer's Injection group
Intraoperative fluid therapy performed with BRS (Sodium Bicarbonate Ringer's Injection)
Sodium Bicarbonate Ringer's Injection
Intraoperative fluid therapy performed with BRS (Sodium Bicarbonate Ringer's Injection)
Sodium Lactated Ringer's Injection group
Intraoperative fluid therapy performed with LRS (Sodium Lactated Ringer's Injection)
Sodium Lactated Ringer's Injection
Intraoperative fluid therapy performed with LRS (Sodium Lactated Ringer's Injection)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sodium Bicarbonate Ringer's Injection
Intraoperative fluid therapy performed with BRS (Sodium Bicarbonate Ringer's Injection)
Sodium Lactated Ringer's Injection
Intraoperative fluid therapy performed with LRS (Sodium Lactated Ringer's Injection)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. patients aged between 20 and 70, signed informed consent form, and are willing to participate in the study.
3. BMI ≤ 30kg/m2.
4. elective major abdominal surgery for the first time (radical resection of ovarian cancer, radical resection of cervical cancer, radical resection of gastric cancer, radical resection of colorectal cancer, radical resection of bladder tumor and radical resection of prostate tumor).
5. NYHA cardiac function grade Ⅰ-Ⅲ.
6. the function of liver and kidney is normal before operation.
7. the blood coagulation function was normal before operation.
8. hemoglobin \> 70g/L.
9. sinus rhythm was detected by electrocardiogram and there were no other malignant arrhythmias.
Exclusion Criteria
2. liver and kidney surgery.
3. complicated with chronic respiratory diseases and FEV1/FVC \< 70%.
4. the operation time is less than 2 hours.
5. patients with mental illness or cognitive impairment.
6. uncontrolled hypertension with blood pressure higher than 180 × 100mmHg.
7. patients with hypothyroidism.
8. pregnant or lactating patients. -
20 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tongji Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shiyong Li
Principal Investigator, Associate professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shiyong Li
Role: PRINCIPAL_INVESTIGATOR
Tongji Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tongji hospital
Wuhan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Pu Zhou, Phd
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ChiCTR2100044465
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.